Current clinical development is also evaluating the MET tyrosine inhibitor capmatinib, initially approved by the FDA in 2020 for the treatment of metastatic non-small-cell lung cancer (NSCLC; particularly tumors with a mutation that leads to MET exon 14 skipping), for potent use in HNC cancer therapy [72]. The gene discussed is MET; the disease is non-small cell lung carcinoma.